ALX Oncology Holdings Inc. Reports Board and Executive Changes
Ticker: ALXO · Form: 8-K · Filed: Jan 17, 2025 · CIK: 1810182
Sentiment: neutral
Topics: management-change, compensation, board-of-directors
TL;DR
ALX Oncology board shakeup and exec comp changes filed. Watch for details.
AI Summary
ALX Oncology Holdings Inc. announced on January 16, 2025, changes in its board of directors and executive compensation arrangements. The filing details the departure of certain officers and directors, the election of new directors, and updates to compensatory arrangements for key personnel. Specific details regarding the individuals involved and the financial implications of these changes are outlined within the report.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy, governance, or financial outlook, potentially impacting investor confidence and stock performance.
Risk Assessment
Risk Level: medium — Changes in leadership and compensation can introduce uncertainty regarding future strategy and performance.
Key Players & Entities
- ALX Oncology Holdings Inc. (company) — Registrant
- January 16, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- South San Francisco, California (location) — Principal Executive Offices
FAQ
What specific roles have been affected by the departure of officers or directors?
The filing indicates changes related to the 'Departure of Directors or Certain Officers' and 'Appointment of Certain Officers,' suggesting shifts in leadership positions, though specific names and roles are detailed within the full report.
Are there any new directors elected to the board?
Yes, the filing explicitly mentions the 'Election of Directors,' indicating that new individuals have been appointed to the board.
What is the nature of the changes in compensatory arrangements?
The report covers 'Compensatory Arrangements of Certain Officers,' implying updates or modifications to the compensation packages for key executives.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this filing occurred on January 16, 2025.
What is the primary business of ALX Oncology Holdings Inc. according to the filing?
ALX Oncology Holdings Inc. is classified under 'PHARMACEUTICAL PREPARATIONS [2834]' according to its Standard Industrial Classification.
Filing Stats: 669 words · 3 min read · ~2 pages · Grade level 14.2 · Accepted 2025-01-17 16:41:26
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share ALXO The Nasdaq Global Se
Filing Documents
- d909443d8k.htm (8-K) — 25KB
- d909443dex101.htm (EX-10.1) — 207KB
- 0001193125-25-008461.txt ( ) — 403KB
- alxo-20250116.xsd (EX-101.SCH) — 3KB
- alxo-20250116_lab.xml (EX-101.LAB) — 17KB
- alxo-20250116_pre.xml (EX-101.PRE) — 11KB
- d909443d8k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. ALX ONCOLOGY HOLDINGS INC Date: January 17, 2025 By: /s/ Jason Lettmann Jason Lettmann Chief Executive Officer -2-